Proteomic differentiation of leukemia cells based on multiplexed arrays and mass

描述（由申请人提供）：虽然一些基因突变可以预测对某些靶向治疗的反应，但单基因检测具有局限性。多种可能导致人类恶性肿瘤的重要信号通路不断被发现和剖析。通路和网络诊断测试具有挑战性，但显然正在进行中。通过这项NIH STTR I期研究，我们将开发一个混合磷酸蛋白质组学平台，在分子水平上区分白血病。该平台具有我们最近推出的两种创新产品，它们基于多功能化的水溶性纳米聚合物，可以在不使用昂贵的磷酸特异性抗体的情况下，对蛋白质磷酸化进行高度选择性，灵敏度和简单的定性和定量评估。由于其尺寸和独特的性质，它还提供了同时多重检测磷酸化和总蛋白量的能力。结合靶向质谱分析，这种混合平台将成为生物医学研究和开发的有力工具，特别是在白血病治疗领域，以及癌症诊断的潜在临床工具。

DESCRIPTION (provided by applicant): Although some gene mutations can predict response to certain targeted therapies, single-gene testing has limits. Multiple important signaling pathways that may be the causes of human malignancy have continuously been discovered and dissected. Pathway and network diagnostic tests are challenging but are clearly on the way. Through this NIH STTR Phase I study, we will develop a hybrid phosphoproteomic platform to differentiate leukemia at the molecular level. The platform features two innovative products recently introduced by us which are based on multi-functionalized water-soluble nanopolymers, allowing for highly selective, sensitive and simple qualitative and quantitative assessment of protein phosphorylation without the use of expensive phosphospecific antibodies. Due to its size and unique properties, it also offers the capability for multiplexed detection of phosphorylation and total protein amount simultaneously. Combined with targeted mass spectrometric analysis, this hybrid platform will be a powerful tool for biomedical research and development, particularly in the field of leukemia treatment, and a potential clinical tool for cancer diagnosis.